Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
brief summary
This study is being done to learn more about an investigational medicine called PF-08634404 when used alone or in combination with other anti-cancer medicines in adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread beyond the lung. PF-08634404 is designed to target two pathways involved in cancer growth and survival. The study will also evaluate combinations with chemotherapy and tarlatamab, an approved immunotherapy that helps the body's immune system recognize and attack small cell lung cancer cells. To join the study, participants must meet the following conditions: * 18 years of age or older. * Have extensive-stage small cell lung cancer confirmed by laboratory testing. * Have measurable disease on imaging scans. * Be in generally good physical condition and have adequate organ function. * For most study groups, have not received prior systemic treatment for extensive-stage small cell lung cancer, although participants who received a single cycle of chemotherapy for life-threatening disease-related symptoms are eligible. The study has two parts: Phase 2 Researchers will evaluate the safety, tolerability, and preliminary anti-cancer activity of PF-08634404. Participants may receive: * PF-08634404 plus chemotherapy, * PF-08634404 plus tarlatamab, or * PF-08634404 plus tarlatamab and chemotherapy. The results will help determine the recommended dose and treatment regimen for future study. Phase 3 Researchers will compare PF-08634404 plus chemotherapy with an approved treatment regimen consisting of atezolizumab plus chemotherapy. The goal is to determine whether PF-08634404 can improve outcomes such as overall survival.
official title
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER